Serial Biotechnology Entrepreneur
Dr. Lanman currently advises or serves as a Board member of a half dozen biotechnology companies, united in the mission to fight cancer. His last three start-up companies, in which his role was Chief Medical Officer, all went public. In his last CMO role for Guardant Health, where he worked from 2014 to 2021, Lanman pioneered testing for circulating cell-free tumor DNA in a simple blood test, or liquid biopsy. The common thread to his career, from physician practice management at Kaiser-Permanente and San Jose Medical Group to the biotechnology industry, is accelerating physician and payer adoption of novel medical technologies that improve patient care. Dr. Lanman has published over 130 peer-reviewed scientific publications.
